AR075380A1 - DERIVATIVES OF N (6-AZA-BICICLO (3.2.1) OCT-1-IL) -ARIL-METIL) -BENZAMIDA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS. - Google Patents
DERIVATIVES OF N (6-AZA-BICICLO (3.2.1) OCT-1-IL) -ARIL-METIL) -BENZAMIDA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.Info
- Publication number
- AR075380A1 AR075380A1 ARP100100345A ARP100100345A AR075380A1 AR 075380 A1 AR075380 A1 AR 075380A1 AR P100100345 A ARP100100345 A AR P100100345A AR P100100345 A ARP100100345 A AR P100100345A AR 075380 A1 AR075380 A1 AR 075380A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- halo
- groups
- group
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 108020004021 3-ketosteroid receptors Proteins 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- -1 NR4R5 Chemical group 0.000 abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 abstract 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Utilizacion en terapéutica y procedimiento de síntesis. Reivindicacion 1: Compuesto de formula general (1): R representa un átomo de hidrogeno o un grupo elegido entre los grupos alquilo C1-6, cicloalquilo C3-7, estando esto grupos eventualmente sustituidos con uno o varios grupos elegidos independientemente el uno del otro entre el átomo de fluor, grupos cicloalquilo C3-7, alquenilo C2-4, fenilo, alcoxi C1-6, hidroxi; estando el grupo fenilo eventualmente sustituido con uno o varios grupos alcoxi; R1 representa un grupo fenilo o naftilo, eventualmente sustituido con uno o varios sustituyentes elegidos independientemente el uno del otro entre los átomos de halogeno, los grupos alquilo C1-6, alcoxi C1-6, halo-alquilo C1-6, NR4R5, NR3C(O)OR4, NR3SO2R4, NR3C(O)R6, hidroxi, halo-alcoxi C1-6, alquil C1-6-tio, alquil C1-6-SO2, fenilo o heteroarilo, estando el grupo fenilo eventualmente sustituido con uno o varios sustituyentes elegidos independientemente entre los átomos de halogeno, los grupos alquilo C1-6, alcoxi C1-6, halo-alquilo C1-6, NR4R5, NR3C(O)OR4, NR3SO2R4, NR3C(O)R6, hidroxi, halo-alcoxi C1-6, alquil C1-6-tio, alquil C1-6 -SO2, estando el grupo heteroarilo eventualmente sustituido con uno o varios sustituyentes elegidos independientemente entre los átomos de halogeno, los grupos alquilo C1-6, alcoxi C1-6, halo-alquilo C1-6, NR4R5; R2 representa uno o varios sustituyentes elegidos entre el átomo de hidrogeno, los átomos de halogeno, los grupos alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-3, halo-alquilo C1-6, alcoxi C1-6, NR4R5, fenilo, heteroarilo, ciano, acetilo, tioalquilo C1-6, alquil C1-6-sulfonilo, carboxi o alcoxi C1-6 carbonilo; estando el grupo fenilo eventualmente sustituido con uno o varios sustituyentes elegidos independientemente entre los átomos de halogeno, los grupos alquilo C1-6, alcoxi C1-6, halo-alquilo C1-4, NR4R5, NR3C(O)OR4, NR3SO2R4, NR3C(O)R6, hidroxi, halo-alcoxi C1-6, alquil C1-6-tio, alquilo C1-6-SO2, estando el grupo heteroarilo eventualmente sustituido con uno o varios sustituyentes elegidos independientemente entre los átomos de halogeno, los grupos alquilo C1-6, alcoxi C1-6, halo-alquilo C1-6, NR4R5; R3, R4 y R5 representan, independientemente el uno del otro, un átomo de hidrogeno o un grupo alquilo C1-6; R6 representa un grupo alquilo C1-6; R4 y R5 pueden formar juntos, con el átomo de nitrogeno que los porta, un ciclo elegido entre los ciclos azetidina, pirrolidina, piperidina, morfolina, tiomorfolina, piperazina, azepina, eventualmente sustituido con un grupo alquilo C1-6; R3 y R4 pueden formar juntos, con los átomos que los portan, un ciclo de 5 o 6 eslabones; R3 y R6 pueden formar juntos, con los átomos que los portan, un ciclo de 5 o 6 eslabones; en el estado de base o de sal de adicion a un ácido.Use in therapy and synthesis procedure. Claim 1: Compound of general formula (1): R represents a hydrogen atom or a group selected from the C1-6 alkyl, C3-7 cycloalkyl groups, this being groups eventually substituted with one or more groups independently selected from each other among the fluorine atom, C3-7 cycloalkyl, C2-4 alkenyl, phenyl, C1-6 alkoxy, hydroxy groups; the phenyl group being optionally substituted with one or more alkoxy groups; R1 represents a phenyl or naphthyl group, optionally substituted with one or more substituents independently selected from each other among the halogen atoms, the C1-6 alkyl, C1-6 alkoxy, halo- C1-6 alkyl, NR4R5, NR3C ( O) OR4, NR3SO2R4, NR3C (O) R6, hydroxy, halo- C1-6 alkoxy, C1-6-thio alkyl, C1-6-SO2 alkyl, phenyl or heteroaryl, the phenyl group being optionally substituted with one or more substituents independently selected from halogen atoms, the groups C1-6 alkyl, C1-6 alkoxy, halo- C1-6 alkyl, NR4R5, NR3C (O) OR4, NR3SO2R4, NR3C (O) R6, hydroxy, halo-C1-alkoxy 6, C1-6-thio alkyl, C1-6 alkyl-SO2, the heteroaryl group being optionally substituted with one or more substituents independently selected from halogen atoms, C1-6 alkyl groups, C1-6 alkoxy, halo-alkyl C1-6, NR4R5; R2 represents one or more substituents chosen from the hydrogen atom, halogen atoms, C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-3 alkyl, halo- C1-6 alkyl, C1-6 alkoxy groups , NR4R5, phenyl, heteroaryl, cyano, acetyl, C1-6 thioalkyl, C1-6 alkyl sulfonyl, carboxy or C1-6 alkoxycarbonyl; the phenyl group being optionally substituted with one or several substituents independently selected from the halogen atoms, the C1-6 alkyl, C1-6 alkoxy, halo-C1-4 alkyl, NR4R5, NR3C (O) OR4, NR3SO2R4, NR3C ( O) R6, hydroxy, C1-6 halo-alkoxy, C1-6-thio alkyl, C1-6-SO2 alkyl, the heteroaryl group being optionally substituted with one or more substituents independently selected from the halogen atoms, C1 alkyl groups -6, C1-6 alkoxy, halo- C1-6 alkyl, NR4R5; R3, R4 and R5 represent, independently of each other, a hydrogen atom or a C1-6 alkyl group; R6 represents a C1-6 alkyl group; R4 and R5 can form together, with the nitrogen atom that carries them, a cycle chosen from the azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, azepine cycles, optionally substituted with a C1-6 alkyl group; R3 and R4 can form together, with the atoms that carry them, a cycle of 5 or 6 links; R3 and R6 can form together, with the atoms that carry them, a cycle of 5 or 6 links; in the base or salt state of acid addition.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0900579A FR2941954B1 (en) | 2009-02-10 | 2009-02-10 | N- (6-AZA-BICYCLO ° 3.2.1! OCT-1-YL) -ARYL-METHYL DERIVATIVES BENZAMIDE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075380A1 true AR075380A1 (en) | 2011-03-30 |
Family
ID=40935769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100345A AR075380A1 (en) | 2009-02-10 | 2010-02-09 | DERIVATIVES OF N (6-AZA-BICICLO (3.2.1) OCT-1-IL) -ARIL-METIL) -BENZAMIDA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2396335A1 (en) |
| JP (1) | JP2012517412A (en) |
| KR (1) | KR20110118813A (en) |
| CN (1) | CN102388050A (en) |
| AR (1) | AR075380A1 (en) |
| AU (1) | AU2010212703A1 (en) |
| BR (1) | BRPI1008544A2 (en) |
| CA (1) | CA2751866A1 (en) |
| FR (1) | FR2941954B1 (en) |
| IL (1) | IL214487A0 (en) |
| MX (1) | MX2011008459A (en) |
| SG (1) | SG173607A1 (en) |
| TW (1) | TW201034667A (en) |
| UY (1) | UY32429A (en) |
| WO (1) | WO2010092287A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2861070B1 (en) * | 2003-10-17 | 2006-01-06 | Sanofi Synthelabo | DERIVATIVES OF N- [PHENYL (PYRROLIDIN-2-YL) METHYL] BENZAMIDE AND N - [(AZEPAN-2-YL) PHENYLMETHYL] BENZAMIDE, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| FR2861076B1 (en) * | 2003-10-17 | 2006-01-06 | Sanofi Synthelabo | N-HETEROCYCLYMETHYLBENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| WO2005058317A1 (en) * | 2003-12-18 | 2005-06-30 | Glaxo Group Limited | Glycine transporter-1 inhibirors |
| AU2006309050B2 (en) * | 2005-10-28 | 2012-08-16 | Merck Sharp & Dohme Corp. | Piperidine glycine transporter inhibitors |
| TW200829238A (en) * | 2006-11-30 | 2008-07-16 | Cenerx Biopharma Inc | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders |
| WO2009013535A1 (en) * | 2007-07-23 | 2009-01-29 | Astrazeneca Ab | 2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor |
-
2009
- 2009-02-10 FR FR0900579A patent/FR2941954B1/en not_active Expired - Fee Related
-
2010
- 2010-02-09 TW TW099104006A patent/TW201034667A/en unknown
- 2010-02-09 CN CN2010800156289A patent/CN102388050A/en active Pending
- 2010-02-09 CA CA2751866A patent/CA2751866A1/en not_active Abandoned
- 2010-02-09 AR ARP100100345A patent/AR075380A1/en unknown
- 2010-02-09 EP EP10708304A patent/EP2396335A1/en not_active Withdrawn
- 2010-02-09 AU AU2010212703A patent/AU2010212703A1/en not_active Abandoned
- 2010-02-09 SG SG2011057213A patent/SG173607A1/en unknown
- 2010-02-09 JP JP2011548759A patent/JP2012517412A/en not_active Withdrawn
- 2010-02-09 BR BRPI1008544A patent/BRPI1008544A2/en not_active Application Discontinuation
- 2010-02-09 WO PCT/FR2010/050204 patent/WO2010092287A1/en not_active Ceased
- 2010-02-09 MX MX2011008459A patent/MX2011008459A/en not_active Application Discontinuation
- 2010-02-09 KR KR1020117021204A patent/KR20110118813A/en not_active Withdrawn
- 2010-02-10 UY UY0001032429A patent/UY32429A/en not_active Application Discontinuation
-
2011
- 2011-08-07 IL IL214487A patent/IL214487A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011008459A (en) | 2011-12-16 |
| UY32429A (en) | 2010-09-30 |
| IL214487A0 (en) | 2011-09-27 |
| TW201034667A (en) | 2010-10-01 |
| FR2941954A1 (en) | 2010-08-13 |
| BRPI1008544A2 (en) | 2016-03-15 |
| KR20110118813A (en) | 2011-11-01 |
| CN102388050A (en) | 2012-03-21 |
| AU2010212703A1 (en) | 2011-09-01 |
| JP2012517412A (en) | 2012-08-02 |
| WO2010092287A1 (en) | 2010-08-19 |
| SG173607A1 (en) | 2011-09-29 |
| FR2941954B1 (en) | 2011-04-08 |
| CA2751866A1 (en) | 2010-08-19 |
| EP2396335A1 (en) | 2011-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074773A1 (en) | PIRIDAZINONAS REPLACED WITH PHENYL IN POSITION 4, ITS USE AS HERBICIDES AND INSECTICIDES IN COMPOSITIONS AND METHODS THAT INCLUDE AND INTERMEDIATE FOR SYNTHESIS. | |
| AR068055A1 (en) | DERIVATIVES OF 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL AND BENCIMIDAZOL ITS PREPARATION PROCEDURE ITS APPLICATION AS MEDICINES PHARMACEUTICAL COMPOSITIONS AND ITS MAIN USE AS MET INHIBITORS | |
| AR076435A1 (en) | COMPOUNDS OF REPLACED INDAZOLS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PROCESSES TO OBTAIN THEMSELVES | |
| AR062677A1 (en) | DERIVATIVES OF BIARIL-SULFONAMIDE, PRODUCTION PROCESSES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM | |
| AR066669A1 (en) | IMIDAZOLONA DERIVATIVES AS INHIBITORS OF BENCIMIDAZOLONA QUIMASA. PHARMACEUTICAL COMPOSITIONS. | |
| UY30105A1 (en) | NEW SULFURED DERIVATIVES OF CYCLIC UREA, ITS PREPARATION AND ITS PHARMACEUTICAL USE AS INHIBITORS OF KINASES. | |
| EA201000413A1 (en) | Method of producing lactamide derivatives, new lactamide derivatives and preparations containing lactamide derivatives | |
| ECSP088731A (en) | DERIVATIVES OF 1,2,4,5-TETRAHIDRO-3H-BENZAZEPINAS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR068479A1 (en) | (CARBOXILALQUILENFENIL) PHENYLOXAMIDS, PROCEDURE FOR PREPARATION AND PHARMACEUTICAL COOMPOSITION | |
| AR049784A1 (en) | SUBSTITUTED DERIVATIVES OF MORFOLINA AND TIOMORFOLINA | |
| CR10643A (en) | DERIVATIVES OF 2-ARIL-6-FENIL-IMIDAZOL [1,2-a] PIRIDINAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| AR061642A1 (en) | DERIVATIVES OF UREAS DE TROPANO, ITS PREPARATION AND ITS APPLICATION IN THERAPEU-TICA, PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS | |
| CO5631432A2 (en) | DERIVATIVES OF N- [PHENYL (PIEPIDIN-2-IL) METIL] BENZAMIDA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| AR069796A1 (en) | DERIVATIVES OF BENCIMIDAZOL, REPLACED BY CARBOXYL OR HYDROXYL, PROCESS TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR059086A1 (en) | DERIVED FROM UREA CYCLES ITS PREPARATION AND ITS PHARMACEUTICAL USE AS INHIBITORS OF KINASES | |
| ECSP077215A (en) | DERIVATIVES OF N- (1H-INDOLIL) -1H-INDOL-2-CARBOXAMIDS, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | |
| AR052568A1 (en) | DERIVATIVES OF PIRAZOLO-PYRIMIDINE AS ANGLOSTS OF MGLUR2 | |
| AR086590A1 (en) | CYCLHEXANONE AND HERBICIDE COMPOUNDS THAT UNDERSTAND THEM | |
| CU20090048A7 (en) | NEW DERIVATIVES OF DIOSMETINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| CU20100157A7 (en) | NEW DIHYDROINDOLONE DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR061835A1 (en) | TETRACICLIC DERIVATIVES, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR075249A1 (en) | DERIVATIVES OF 6- (6-O-SUBSTITUTED-TRIAZOLOPIRIDAZINA-SULFANIL) BENZOTIAZOLES AND BENCIMIDAZOLES, METHOD OF PREPARATION OF THE SAME AND INTERMEDIARIES OF SUCH SYNTHESIS, MEDICINES CONTAINING THEM AND USE OF THE MYSTS AND ALERTS IN THE TRACKS, ALERTS OTHER DISEASES. | |
| CO6150157A2 (en) | DERIVATIVES OF 7-ALQUINIL-1,8- NAFTIRIDONAS ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| CR9499A (en) | NEW DERIVATIVES OF PHENYLPIRIDINYLPIPERAZINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR086037A1 (en) | DERIVATIVES OF PIRAZOLIDIN-3-ONA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |